SIGA Technologies

The board of directors of SIGA Technologies has approved a cash dividend of $0.60 per common share, payable on April 23, 2026 to shareholders of record at the close of trading on April 7, 2026. The payout matches the special dividend announced in April 2025 and, according to InvestingPro, represents a yield of about 12%. The company shows a high liquidity ratio (current ratio 11.83), while the stock, at $4.81, is trading near its 52-week low and has fallen roughly 46% over the past six months. SIGA Technologies is in the commercialization phase and focuses on drugs for the treatment and prevention of infectious diseases, particularly orthopoxviruses. » Más en de.investing.com

SIGA Technologies reported 2025 annual revenue of $95 million and a net profit of $23 million, with a cash balance of $155 million and no debt. However, in the fourth quarter the company posted a loss per share of -$0.08, highlighting quarterly volatility due to irregular government procurement. Investor reactions were mixed: the stock fell in after-hours trading but recovered in pre-market trading. Remaining risks include regulatory uncertainty in Europe for the Mpox indication and strong dependence on U.S. government contracts. » Más en de.investing.com

SIGA Technologies recorded total revenue of $95 million in 2025, including $88 million in product revenue, and net income of $23 million (earnings per share $0.32). The company holds $155 million in cash, is debt-free, and delivered TPOXX worth $79 million to the U.S. government. Outstanding government orders of $26 million for 2026, plus $27 million in grants for pediatric and intravenous formulations, underpin the optimistic outlook. » Más en de.investing.com